MedTrace Logo

Bryophyllum Pinnatum Versus Solifenacin Versus Placebo for Overactive Bladder

NCT02129816 · Status: TERMINATED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2017-10-26

No results posted yet for this study

Summary

Overactive bladder (OAB) is an enigmatic condition that is treated symptomatically with anticholinergic drugs (gold standard 2013). In a clinical pilot study was found to be a trend for a higher reduction of the micturition frequency in the Bryophyllum pinnatum group - treated with chewing tablets containing 50% of dried BP leaf press juice - than in the placebo group (n=20, p=0.064) Hypothesis: To test the superior effectivity of Bryophyllum versus Placebo in the treatment of OAB with the needed number (Purpose 1) and to assess in an experimental arm the side effects of BP in comparison to the standard drug (Vesicare) in a clincial trial (Purpose 2).

Conditions

Interventions

DRUG

Bryophyllum

Sponsors & Collaborators

  • PD Dr. med. Verena Geissbühler

    collaborator UNKNOWN

  • Prof. pharm. Ursula von Mandach

    collaborator UNKNOWN

  • Dr. med. David Scheiner

    collaborator UNKNOWN

  • Dr. med. Matthias Werner

    collaborator UNKNOWN

  • University of Zurich

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
40 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-05-31
Primary Completion
2016-04-20
Completion
2017-07-09

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02129816 on ClinicalTrials.gov